Drugs / mesenchymal cells
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01207193 | Oct 2009 → Oct 2011 | expansile bone lesions | Royan Institute | Completed | No outcome recorded |
| Phase 1 | NCT01210950 | Sep 2009 → Dec 2013 | — | Royan Institute | Completed | No outcome recorded |
| Phase 1 | NCT01206179 | Mar 2009 → Mar 2011 | — | Royan Institute | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04366271 | May → Jul 2020 | COVID-19 | Hospital Infantil Universitario Niño Jesús, Madrid, Spain | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT03743155 | Dec 2018 → May 2019 | — | Institut de Terapia Regenerativa Tissular | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mesenchymal cells | “mesenchymal cells and Plasma reach Protein are injected to the callus center” NCT01210950 ↗4“Patients with bone cyst defect are injected with mesenchymal cells.” NCT01207193 ↗ “Injection of mesenchymal cells in fractured zone” NCT01206179 ↗ |
| Modality | Cell therapy | “mesenchymal stem cells” NCT01207193 ↗ |
| Route | Other | “percutaneous injection of mesenchymal stem cells to the site of fracture is performed” NCT01206179 ↗ |